RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Core Insights - RenovoRx, Inc. is experiencing commercial momentum with its RenovoCath device being integrated into U.S. cancer centers' oncology treatment programs, enhancing chemotherapy delivery near tumor sites [1][2][5] Group 1: Commercial Adoption - The number of active commercial cancer centers using RenovoCath has increased from five in September 2025 to nine, with notable additions including City of Hope Cancer Center and Moffitt Cancer Center [2] - RenovoRx generated approximately $900,000 in sales revenue through September 2025, indicating a positive trend in commercialization efforts [5][12] Group 2: Clinical Impact - The TAMP therapy platform, enabled by RenovoCath, is highlighted for its potential to improve treatment for difficult-to-treat tumors, such as locally advanced pancreatic cancer [3][10] - The ongoing Phase III TIGeR-PaC trial is evaluating the intra-arterial delivery of gemcitabine via RenovoCath for treating locally advanced pancreatic cancer [10][13] Group 3: Strategic Developments - RenovoRx has established a dedicated commercial team to enhance its go-to-market strategy, which has led to accelerating adoption of RenovoCath [6] - The company is focusing on lessons learned from 2025 to drive revenue growth in 2026, emphasizing physician demand and effective training initiatives [6] Group 4: Future Prospects - The company is exploring further revenue-generating activities and potential partnerships to meet anticipated demand for RenovoCath [12] - RenovoCath has received Orphan Drug Designation for pancreatic cancer, which could provide seven years of market exclusivity upon FDA approval [14]